AstraZeneca Shifts Abandoned GI Developmental Compounds To New Affiliate
This article was originally published in The Pink Sheet Daily
Executive Summary
New company Albireo will be financed initially with $27 million from three growth capital firms.
You may also be interested in...
Deals Of The Week: Janssen/CorImmun, AstraZeneca/Cellworks, Ferring/Albireo
To the familiar sounds of the Fourth of July and mid-summer, Deals of the Week adds another: the sound of the next shoe dropping in biopharmaceutical merger-and-acquisition activity. What happens next after the $5 billion-plus buyout of Amylin by Bristol-Myers?
Tranzyme’s TZP-101 Proof-of-Concept Study Bodes Well For Deal, CEO Says
Compound’s promising Phase IIb results should pave the way to an exit for the North Carolina biotech.
Tranzyme’s TZP-101 Proof-of-Concept Study Bodes Well For Deal, CEO Says
Compound’s promising Phase IIb results should pave the way to an exit for the North Carolina biotech.